The global anti-obesity drugs market size was estimated to be USD 3.48 billion in 2023 and is expected to reach at USD 16.76 billion by 2034 with a CAGR of 15.36% during the forecast period 2024-2034. Growing prevalence of obesity, surge in number of clinical trials for the treatment of obesity, increasing research & development activities for the development of novel drugs that target both obesity and type 2 diabetes, rising adoption of sedentary lifestyles & unhealthy eating habits, growing approvals of chronic weight management drugs, and increasing launch of novel drugs are some of the key factors boosting the market growth.
Increasing launch of novel drugs is predicted to boost the market growth during the forecast period. It is anticipated that there would be a significant increase in prospects for market vendors to produce new goods due to the growing need for long-lasting medications. For instance, in June 2023, Retatrutide, an experimental medication developed by Eli Lilly Company, shows promise in addressing both obesity and type 2 diabetes. It can be administered through a once-weekly injection and operates by reducing appetite to promote weight loss in individuals with diabetes.
By drug, prescription drugs was the highest revenue-grossing segment in the global anti-obesity drugs market in 2023 owing to growing prevalence of obesity, surge in number of anti-obesity drugs in the pipeline phase, rising research & development activities, increasing awareness of prescription medicine, and growing approvals by regulatory bodies. For instance, in October 2022, Eli Lilly and Company has stated that the U.S. Food and Drug Administration (FDA) has provided Fast Track designation for the study of tirzepatide in adults who have obesity or are overweight with comorbidities related to weight. Additionally, Over the counter drugs is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for self-medications & drugs and rising approvals of over-the-counter drugs by regulatory bodies.
By mechanism of action, centrally acting anti-obesity drugs was the highest revenue-grossing segment in the global anti-obesity drugs market in 2023 owing to growing awareness regarding the availability of centrally acting anti-obesity drugs among population and increasing product approvals by regulatory bodies. For instance, in June 2022, The U.S. Food and Drug Administration has granted approval for an expanded use of Qsymia, allowing it to be used as a supplementary treatment for chronic weight management in pediatric patients aged 12 and above who are classified as obese. Obesity is defined as having a body mass index (BMI) at or above the 95th percentile for their age and gender. Qsymia should be employed in conjunction with a reduced-calorie diet and increased physical activity. Additionally, Peripherally acting anti-obesity drugs is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of obesity and rising research & development activities for the development of peripherally acting novel drugs.
By route of administration, oral route was the highest revenue-grossing segment in the global anti-obesity drugs market in 2023 owing to the growing demand for self-administration, increasing launch of new products, surge in number of clinical trials, and rising focus on development of novel products by market players. For instance, in June 2023, Pfizer Inc. has declared its intention to advance a specific oral late-stage candidate, a glucagon-like peptide-1 receptor agonist (GLP-1-RA), through additional clinical phases. This is aimed at potentially treating adults diagnosed with both obesity and Type 2 diabetes mellitus (T2DM). Additionally, Subcutaneous route is predicted to grow at fastest CAGR during the forecast period owing to the rising convenience & safety offered by subcutaneous route, increasing adoption of minimally invasive procedures, and growing focus on drug development by major market players.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global anti-obesity drugs market in 2023 owing to increasing prevalence of obesity, growing demand for prescription based anti-obesity drugs, rising regulatory approvals, and surge in collaborations within market players. For instance, in August 2023, Novo Nordisk's acquisition of Inversago Pharma aims to facilitate the creation of novel treatments for individuals dealing with obesity, diabetes, and other significant metabolic conditions. Additionally, Retail pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the discounts provided by the manufacturers for medication, growing healthcare expenditure, and surge in number of pharmacy’s retail chains.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in number of obese populations, rising healthcare expenditure, growing awareness regarding severe chronic diseases related to obesity among the population, increasing number of clinical trials, surge in investment by market players in research & development activities, and rising initiatives by market players. For instance, in November 2022, Novo Nordisk has announced plans to enhance its production capacity for upcoming obesity medications while placing less emphasis on marketing and promotion, especially in light of the problematic market launch of its Wegovy injectable last year. The company explained that it had to undergo an extended manufacturing overhaul due to complications faced by a subcontractor during the filling process of Wegovy injectable pens towards the end of the previous year. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for anti-obesity drugs, rising prevalence of obesity, increasing awareness about anti-obesity drugs, surge in investment & collaborations by market players, and growing research & development activities. For instance, in May 2023, In a phase 2 clinical trial conducted by Innovent Biologics, Inc., the use of a 9 mg dose of mazdutide (IB1362) resulted in favorable results among Chinese adults diagnosed with obesity.
Increasing launch of novel drugs is predicted to boost the market growth during the forecast period. It is anticipated that there would be a significant increase in prospects for market vendors to produce new goods due to the growing need for long-lasting medications. For instance, in June 2023, Retatrutide, an experimental medication developed by Eli Lilly Company, shows promise in addressing both obesity and type 2 diabetes. It can be administered through a once-weekly injection and operates by reducing appetite to promote weight loss in individuals with diabetes.
By drug, prescription drugs was the highest revenue-grossing segment in the global anti-obesity drugs market in 2023 owing to growing prevalence of obesity, surge in number of anti-obesity drugs in the pipeline phase, rising research & development activities, increasing awareness of prescription medicine, and growing approvals by regulatory bodies. For instance, in October 2022, Eli Lilly and Company has stated that the U.S. Food and Drug Administration (FDA) has provided Fast Track designation for the study of tirzepatide in adults who have obesity or are overweight with comorbidities related to weight. Additionally, Over the counter drugs is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for self-medications & drugs and rising approvals of over-the-counter drugs by regulatory bodies.
By mechanism of action, centrally acting anti-obesity drugs was the highest revenue-grossing segment in the global anti-obesity drugs market in 2023 owing to growing awareness regarding the availability of centrally acting anti-obesity drugs among population and increasing product approvals by regulatory bodies. For instance, in June 2022, The U.S. Food and Drug Administration has granted approval for an expanded use of Qsymia, allowing it to be used as a supplementary treatment for chronic weight management in pediatric patients aged 12 and above who are classified as obese. Obesity is defined as having a body mass index (BMI) at or above the 95th percentile for their age and gender. Qsymia should be employed in conjunction with a reduced-calorie diet and increased physical activity. Additionally, Peripherally acting anti-obesity drugs is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of obesity and rising research & development activities for the development of peripherally acting novel drugs.
By route of administration, oral route was the highest revenue-grossing segment in the global anti-obesity drugs market in 2023 owing to the growing demand for self-administration, increasing launch of new products, surge in number of clinical trials, and rising focus on development of novel products by market players. For instance, in June 2023, Pfizer Inc. has declared its intention to advance a specific oral late-stage candidate, a glucagon-like peptide-1 receptor agonist (GLP-1-RA), through additional clinical phases. This is aimed at potentially treating adults diagnosed with both obesity and Type 2 diabetes mellitus (T2DM). Additionally, Subcutaneous route is predicted to grow at fastest CAGR during the forecast period owing to the rising convenience & safety offered by subcutaneous route, increasing adoption of minimally invasive procedures, and growing focus on drug development by major market players.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global anti-obesity drugs market in 2023 owing to increasing prevalence of obesity, growing demand for prescription based anti-obesity drugs, rising regulatory approvals, and surge in collaborations within market players. For instance, in August 2023, Novo Nordisk's acquisition of Inversago Pharma aims to facilitate the creation of novel treatments for individuals dealing with obesity, diabetes, and other significant metabolic conditions. Additionally, Retail pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the discounts provided by the manufacturers for medication, growing healthcare expenditure, and surge in number of pharmacy’s retail chains.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in number of obese populations, rising healthcare expenditure, growing awareness regarding severe chronic diseases related to obesity among the population, increasing number of clinical trials, surge in investment by market players in research & development activities, and rising initiatives by market players. For instance, in November 2022, Novo Nordisk has announced plans to enhance its production capacity for upcoming obesity medications while placing less emphasis on marketing and promotion, especially in light of the problematic market launch of its Wegovy injectable last year. The company explained that it had to undergo an extended manufacturing overhaul due to complications faced by a subcontractor during the filling process of Wegovy injectable pens towards the end of the previous year. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for anti-obesity drugs, rising prevalence of obesity, increasing awareness about anti-obesity drugs, surge in investment & collaborations by market players, and growing research & development activities. For instance, in May 2023, In a phase 2 clinical trial conducted by Innovent Biologics, Inc., the use of a 9 mg dose of mazdutide (IB1362) resulted in favorable results among Chinese adults diagnosed with obesity.
Segmentation: Anti-Obesity Drugs Market Report 2022 - 2033
Anti-Obesity Drugs Market Analysis & Forecast by Drug 2023 - 2034 (Revenue USD Bn)
- Over the Counter Drugs
- Prescription Drugs
Anti-Obesity Drugs Market Analysis & Forecast by Mechanism of Action 2023 - 2034 (Revenue USD Bn)
- Peripherally Acting Anti-Obesity Drugs
- Centrally Acting Anti-Obesity Drugs
Anti-Obesity Drugs Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Subcutaneous Route
- Oral Route
Anti-Obesity Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Anti-Obesity Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Anti-Obesity Drugs Market: Drug Estimates & Trend Analysis
8. Anti-Obesity Drugs Market: Mechanism of Action Estimates & Trend Analysis
9. Anti-Obesity Drugs Market: Route of Administration Estimates & Trend Analysis
10. Anti-Obesity Drugs Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Anti-Obesity Drugs Market
13. Europe Global Anti-Obesity Drugs Market
14. Asia Pacific Global Anti-Obesity Drugs Market
15. Latin America Global Anti-Obesity Drugs Market
16. MEA Global Anti-Obesity Drugs Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Gelesis Holdings Inc.
- Novo Nordisk A/S
- CHEPLAPHARM Arzneimittel GmbH
- GlaxoSmithKline plc
- Rhythm Pharmaceuticals
- Pfizer Inc.
- Eli Lilly and Company
- Currax Pharmaceuticals LLC
- Vivus LLC.
- Boehringer Ingelheim International GmbH
- KVK Tech Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.48 Billion |
| Forecasted Market Value ( USD | $ 16.76 Billion |
| Compound Annual Growth Rate | 15.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
